Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications

Jack Kloeber (), Alex Stojanovic () and C. Kwon Kim ()
Additional contact information
Jack Kloeber: Kromite LLC
Alex Stojanovic: Phosphagenics
C. Kwon Kim: Kromite LLC

Chapter Chapter 8 in Optimization of Pharmaceutical R&D Programs and Portfolios, 2015, pp 123-139 from Springer

Abstract: Abstract In this chapter, we address portfolio optimization at a sub-portfolio level. Even a “mini” portfolio—such as a single molecule with numerous indication opportunities—can pose a significant challenge to an organization; there are many interdependencies, correlations, and synergies to consider, weigh, and trade off. Here we present a case study that considers the challenge of optimizing this sub-portfolio by determining the best sequence of three potential indications. The same methods can be applied to a molecule with even more indication opportunities, a group of related molecules, or an entire portfolio.

Keywords: decision analysis; indication sequencing; clinical development; MODA; decision tree; risk adjusted valuation; portfolio optimization; pipeline planning (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-09075-7_8

Ordering information: This item can be ordered from
http://www.springer.com/9783319090757

DOI: 10.1007/978-3-319-09075-7_8

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().